Phenotypes Associated with This Genotype

Genotype
MGI:5521486

• Allelic Composition: Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0; Tg(Pdx1-cre)6Tuv/0; Tg(tetO-MYC)36Bop/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:197052 )

• mutants become moribund before they develop large tumors

neoplasm

increased pancreas tumor incidence ( J:197052 )

• mice develop pancreatic tumors as early as 14 days post partum

• all mice develop pancreatic neoplasms in less than 5 months

• 43% of mutants develop only ductal lesions, 46% of mutants have both ductal lesions and poorly differentiated carcinomas, and 11% of mutants exhibit only poorly differentiated adenocarcinomas

• 40-50 day old mutants with palpable pancreatic neoplasms treated with doxycycline for 7 days show cancer regression, however tumor-associated stroma does not remodel/regress

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinomas (PDACs) with sporadic metastasis to the liver

• 11% of mutants exhibit exclusively poorly differentiated adenocarcinomas that can metastasize to the liver, diaphragm, and lung

• 46% of mutants have both ductal lesions and poorly differentiated carcinomas, with a few mutants having moderately differentiated lesions that have an acinar-like appearance

increased pancreatic intraepithelial neoplasia incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinoma (PDACs) with sporadic metastasis to the liver

increased metastatic potential ( J:197052 )

• pancreatic ductal adenocarcinomas metastasize to the liver, diaphragm, and lung

endocrine/exocrine glands

increased pancreas tumor incidence ( J:197052 )

• mice develop pancreatic tumors as early as 14 days post partum

• all mice develop pancreatic neoplasms in less than 5 months

• 43% of mutants develop only ductal lesions, 46% of mutants have both ductal lesions and poorly differentiated carcinomas, and 11% of mutants exhibit only poorly differentiated adenocarcinomas

• 40-50 day old mutants with palpable pancreatic neoplasms treated with doxycycline for 7 days show cancer regression, however tumor-associated stroma does not remodel/regress

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinomas (PDACs) with sporadic metastasis to the liver

• 11% of mutants exhibit exclusively poorly differentiated adenocarcinomas that can metastasize to the liver, diaphragm, and lung

• 46% of mutants have both ductal lesions and poorly differentiated carcinomas, with a few mutants having moderately differentiated lesions that have an acinar-like appearance

increased pancreatic intraepithelial neoplasia incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinoma (PDACs) with sporadic metastasis to the liver

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic carcinoma		DOID:4905	OMIM:260350	J:197052